
Snipr Biome has great expectations for 2022 following the US Food and Drug Administration (FDA) approval of the company's application to initiate a phase I clinical trial with its first development candidate, which will be conducted in the US.
CEO Christian Grøndahl expects that Snipr Biome will begin the study in the first six months of the year, and that the company will have the first results before the end of 2022.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app